Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ClinMet Metabolomics Platform Offers Unique Insights into Diabetic Kidney Disease

Published: Friday, December 13, 2013
Last Updated: Friday, December 13, 2013
Bookmark and Share
Findings overturn previous belief regarding relationship of mitochondrial activity and diabetic complications.

Researchers from The University of California, San Diego School of Medicine have published new metabolomics research that uncovers a novel, characteristic and highly consistent biochemical signature in urine associated with diabetic kidney disease. The findings, which form a foundation of ClinMet’s proprietary Clinical Metabolomics platform, have implications for the identification of clinically useful biomarkers for kidney function and for sharpening drug development and clinical trials related to chronic kidney disease, as well as to diabetes, obesity and cardiovascular disease.

The new research, authored by U.C. San Diego professor and ClinMet scientific founder, Kumar Sharma, M.D., F.A.H.A (Director of the Center for Renal Translational Medicine, Division of Nephrology-Hypertension and the Institute of Metabolomic Medicine) and colleagues, appears online in the Journal of the American Society of Nephrology. ClinMet has an exclusive license to use this set of metabolites in drug development and other applications, based on patents filed by UC San Diego.

The researchers quantified 94 urine metabolites in subjects with diabetes (type 1 or type 2) and chronic kidney disease (CKD), subjects with diabetes but no kidney disease, and healthy controls. They found that 13 of the metabolites were significantly different in those with disease compared to healthy controls (p values between 10-3 to 10-18), and 12 of 13 remained highly significant when compared to patients with type 1 or type 2 diabetes and no CKD. Moreover, 12 of the 13 metabolites were linked to mitochondrial metabolism and suggested global suppression of mitochondrial activity in the subjects with CKD relative to healthy individuals. This conclusion is in sharp contrast to prevailing beliefs about excess mitochondrial activity having a causal relationship to diabetic complications. The conclusions based on the urine metabolomic studies were independently validated based on protein and DNA analysis, indicating reduced mitochondrial content in the kidneys of patients with diabetic kidney disease.

“It is clear from this study that urine- and plasma-based metabolomics can be a rich source of biomarkers for understanding and treating diabetic kidney disease and possibly for related cardiovascular complications,” said Dr. Sharma. “This approach also offers direct insights into biochemical pathways linked to kidney dysfunction.”

Power of Clinical Metabolomics
“Genomics can help predict overall disease risk or a patient’s potential response to a drug, but cannot capture the effects that changes in diet, environmental factors, or other illnesses have on disease progression or improvement,” said Yesh Subramanian, President, Chief Executive Officer and co-founder of ClinMet. “Clinical metabolomics, in contrast, lets us quickly see biochemically what is happening in specific disease pathways over time and in the context of other factors affecting a patient’s health, including drug therapy. This makes clinical metabolomics a highly actionable platform for translational research and drug development.”

“We see clinical metabolomics enabling our pharmaceutical and biotech customers to effectively implement precision medicine today,” Mr. Subramanian noted. “The ability to predict which patients are likely to better respond to specific treatments holds immense promise for sharpening Phase 2 and 3 clinical trials now, and for improving clinical medicine in the future.” 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Tool Brings Personalized Medicine Closer
Scientists from EPFL and ETHZ have developed a powerful tool for exploring and determining the inherent biological differences between individuals, which overcomes a major hurdle for personalized medicine.
Rapid Retrieval of Live, Infectious Pathogens from Clinical Samples
An engineered pathogen-binding protein enables rapid isolation of infectious bacteria from joint fluids and accelerates their identification.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Detecting Fake Parmesan Cheeses
Scientists report on a way to catch adulteration of the regional artisanal products.
The Need for Speed
Evaluating MALDI-TOF as a high-throughput screening technology for the pharmaceutical industry.
Process Analysis in Real Time
With a real-time mass spectrometer developed by Fraunhofer researchers, it has become possible for the first time to analyze up to 30 components simultaneously from the gas phase and a liquid, including in-situ analysis.
Triple-Negative Breast Cancer Target Is Found
Researchers at UC Berkeley discover a target that drives cancer metabolism in triple-negative breast cancer.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!